Latest Intelligence on Genitourinary and Osteoporosis in Europe

Published within

« | 1 | 2 | 3 | 4 | » »|

Type Product title / description Pub Price
Expert View
Expert View

"The pill" goes natural with potential new bestseller

Teva has announced the EU approval of NOMAC/E2, the first monophasic contraceptive with natural estrogen. The perceived increased safety of natural estrogen and a global launch will drive sales of the product, making it a leading hormonal contraceptive brand. To maximize its potential, however, Teva needs to show improved safety over synthetic estrogen contraceptives in post-marketing studies.

Published By Datamonitor
03 Aug 2011
CommentWire
CommentWire

Abbott: safeguarding market leadership through elagolix deal

Global healthcare firm Abbott has boosted its gonadotropin releasing hormones pipeline through a deal with Neurocrine for the continued development of new promising candidate elagolix. The partnership is favorable for both parties, with Abbott seeking to maintain its endometriosis market leadership after Lupron's patent expiry in 2014.

Published By Datamonitor
17 Jun 2010
Expert View
Expert View

Amgen and GlaxoSmithKline dominate proceedings at ECCEO-11 with Prolia presentations

Amgen's and GlaxoSmithKline's main goal at ECCEO-11 was to educate delegates regarding Prolia's unique mechanism of action and its key differentiators, such as its mode of administration and efficacy. Long-term safety data were presented in an attempt to address Phase III trial issues; however, it is unlikely that physicians will be persuaded to use Prolia as a first-line therapy in the near term.

Published By Datamonitor
06 Apr 2011
Expert View
Expert View

Amgen promotes novel offering at World Congress on Osteoporosis

The 2010 International Osteoporosis Foundation World Congress on Osteoporosis and 10th European Congress on Clinical and Economical Aspects of Osteoporosis and Osteoarthritis in May was the most important meeting of the year in the osteoporosis arena. While no new groundbreaking data for the drug were revealed, Amgen used the congress to promote its novel monoclonal antibody denosumab.

Published By Datamonitor
18 May 2010
CommentWire
CommentWire

Amgen: denosumab deal maximizes potential in tough European market

Amgen has announced that it has formed a partnership with GlaxoSmithKline to commercialize denosumab for the treatment of postmenopausal osteoporosis in Europe and emerging markets. While this partnership increases denosumab's potential in the EU, the challenge will be to convince payers that the new monoclonal antibody provides a clear clinical advantage over cheap and effective alternatives.

Published By Datamonitor
29 Jul 2009
Expert View
Expert View

Astellas: positive Phase III data bode well for novel overactive bladder candidate

Astellas has presented positive new Phase III data for mirabegron, a drug that treats overactive bladder symptoms. The efficacy and safety profile suggests that the drug is well positioned to address some of the unmet needs in the overactive bladder market, and should cardiovascular safety be established, mirabegron is likely to become a leading treatment option.

Published By Datamonitor
21 Mar 2011
Expert View
Expert View

AUA 2010: companies aim to maintain presence in lucrative overactive bladder arena

Overactive bladder was a key area of focus at this year's meeting of the American Urological Association. In attending the conference, Datamonitor identified new strategies from Pfizer and Watson Pharmaceuticals which aim to put these companies' drugs at the forefront of treatment in this lucrative disease area.

Published By Datamonitor
04 Jun 2010
Expert View
Expert View

AUA 2010: encouraging new drugs in benign prostatic hyperplasia but challenges remain

Datamonitor attended this year's meeting of the American Urological Association, at which data were presented for two promising new candidates developed for the treatment of benign prostatic hyperplasia. Specifically, Watson Pharmaceuticals outlined the differentiators for its new treatment Rapaflo, while Nymox used the meeting to present new data for its pipeline drug NX-1207.

Published By Datamonitor
04 Jun 2010
CommentWire
CommentWire

Ferring: strong R&D base for next generation incontinence treatment

Ferring's next generation of antidiuretics to treat urinary incontinence could make use of pioneering research by Nobel Laureate Professor Agre. The company's close relationship with academia and its own long history of research in the urinary incontinence field should strengthen its position as a leading urology player.

Published By Datamonitor
01 Mar 2004
Expert View
Expert View

FIGO 2009: Bayer-Schering maintains leadership in contraception

Datamonitor attended this year's International Federation of Gynecology and Obstetrics World Congress in Cape Town to assess the state of the women's healthcare market. The overwhelming presence of Bayer-Schering at the conference confirms the company's strength in the contraceptives field and its commitment to maintaining its market-leading position.

Published By Datamonitor
13 Oct 2009

« | 1 | 2 | 3 | 4 | » »|

No help is available.